ELKIN VLADIMIR LEMOS LUENGAS
MD, Ms, MA,MBA, PhD.
Bogotá,DC
Summary
Enthusiastic MD, PhD with broad experience in Pharmaceutical company in different medical roles with high performance, very interested in Lead - Infectious Disease, Medical Affairs jobs, eager to contribute to team success through hard work, attention to detail and excellent organizational skills. Clear understanding of Medical Affairs Tasks and training in Infectious Diseases. Motivated to learn, grow and excel in US.
Overview
20
20
years of professional experience
20
20
years of post-secondary education
3
3
Certificates
2
2
Languages
Work History
HOSPITAL MEDICAL LEAD COLOMBIA-VENEZUELA
PFIZER S.A.S
BOGOTA, COLOMBIA, CUNDINAMARCA
02.2021 - Current
- Medical Activities focused in patient first! as well as humanistic outcomes.
- Used coordination,planning skills to achieve results according to schedule.
- Local/Subregional/ Regional, Medical point-of-responsibility providing matrix leadership within cross-functional Local/Subregional/ Regional, clinical development team including innovate to bring therapies to patients that significantly improve their lives.
- Carried out day-day-day duties accurately as well as efficiently.
- Prepared variety of different written communications, reports,documents to ensure smooth operations.
- Devoted special emphasis to punctuality,worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Worked closely with [Internal and External] customers to understand needs provide excellent service.
- Self-identify needs, formulate/execute plan to address .
- Strong ability to communicate to team on topics with divergent views respectfully as well as productive manner.
- Leading positioning of Pfizer as ally of choice in health management through leadership medical / scientific strategies of institutional portfolio of current,future products, based on customer needs,framed in corporate, local, values of Pfizer policies.
- Expert scientist portfolio in charge: Contribution,Leadership as leading expert in knowledge and management of medical, scientific strategies, through continuous,solid advice in development of projects portfolio in charge (Anti Infective), domain management information available regarding trademarks (medical studies, web pages, product portfolios, investigations, etc.
- Scientific Medical Strategies: Design, lead, implement and Scientific doctor for hospital portfolio strategies: Infection prevention & Control strategies , Health partner coordination liaison , according to medical requirements, patients, health agencies, in order to provide services exceed expectations,maximize the performance of brands. (Includes continuing medical education program, forming expert committees, development and implementation of treatment guidelines, advice in the construction of promotional material.
- Comprehensive approach: active contribution from scientific point of view in development,implementation of medical strategies. 5) Strategic alliances: ensure solid relationships and partnerships with KOLs, scientific societies, health institutions and other key development portfolio by authorities.
- New products: Design, develop, implement scientific medical strategies for new brands, based on needs of physicians, patients,health agencies.
- Clinical Research, Health Economics: Participate in conjunction with clinical research area, areas of health economics in development of projects, plans, programs in order to contribute,create value in portfolio in charge.
- Regulatory: Medical support to regulatory strategy,products by developing, interaction with Colombian’s regulatory agency (INVIMA); Medical lead for regulatory submissions,responses to Boards of Health.
- Provide medical leadership in development clinical study protocol,clinical study reports, RWE, Health Economics etc
- Supervising Medical Scientific LiaIson activities.
- Supervising pharmacology resident activities in medical affairs department.
- Co-creates as well as approves Locally/regionally promotional material.
- Zinforo /Zavicefta development plan for launching; including all knowledge generating activities (ie, value dossier,registration program, post approval commitments,lifecycle indications & phase 4 clinical studies.
- Accountable Locally for delivery of Global/Regional Medical Plan,ensuring single, aligned medical strategy, position on risk-benefit of asset, communication of that position internally & externally.
- Leading Local Pfizer position on new data, competing assets, developing resistance, possible label changes, data generation.
- Worked within applicable standards, policies and regulatory guidelines to promote safe working environment.
- Devoted special emphasis to punctuality and worked to maintain outstanding attendance record.
- Resolved conflicts and negotiated mutually beneficial agreements between parties.
- Used critical thinking to break down problems, evaluate solutions and make decisions.
- Leader in Subregional/ Regional Activities a) First Zavicefta(Ceftazidime/Avibactam) Virtual Speaker Training LATAM based in Colombia 2020 Rol Leading all alignments, medical activities according to legal, local compliance with ethics,as well as responsibility. b) Data Generation for ATLAS in LATAM 2020. Rol Worked closely with IHMA (Third party) to align medical message to LATAM. Outcome: Poster Presented IDWEEK 2020.In vitro Activity of Ceftazidime-Avibactam Against Enterobacterales, Pseudomonas aeruginosa collected in LATAM as part of ATLAS Global Surveillance Program 2017-2019 Rol: Coauthor c) SIXBOX Project Leading publication team. d) INFOCUS (LATAM Regional Antifungal Conference 2018). Rol: Organizing medical activities like chairman. e) LATAM Zinforo patient profile Rol: Creating 7 Patient Profile for Community Acquired Pneumonia (CAP) And Skin/ Skin Structure Infections (SSI):f) Supporting Antimicrobial Stewardship Activities in LATAM with LASCONET LATAM network. Rol: (Worked closely with a complex matrixed team's) Patient Flow for LATAM anti-invectives Rol: Analysis any complex epidemiological data based in Antimicrobial resistance. h) Capitation Model for LATAM Rol: Analysis some complex epidemiological data based in Antimicrobial resistance i) Worked closely with LATAM training to review current training materials for all LATAM Reps in Hospital portfolio. Rol: Co-creates as well as approves Locally/regionally promotional material.
- Leading solidarity Clinical Trial(COVID19) in Colombia with Word Health Organization (WHO) as part of Medical Service Covid 19 Pfizer. Rol. Principal Investigator.
MEDICAL MANAGER ANTI-INFECTIVES
PFIZER SAS
BOGOTA, COLOMBIA, CUNDINAMARCA
03.2016 - 02.2022
- Medical Activities focused in patient first! as well as humanistic outcomes.
- Used coordination,planning skills to achieve results according to schedule.
- Local/Subregional/ Regional, Medical point-of-responsibility providing matrix leadership within cross-functional Local/Subregional/ Regional, clinical development team including innovate to bring therapies to patients that significantly improve their lives.
- Carried out day-to-day duties accurately as well as efficiently.
Prepared variety of different written communications, reports,documents to ensure smooth operations. - Devoted special emphasis to punctuality,worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Worked closely with [Internal and External] customers to understand needs provide excellent service.
- Self-identify needs, formulate/execute plan to address .
Strong ability to communicate to team on topics with divergent views respectfully as well as productive manner. - Leading positioning of Pfizer as ally of choice in health management through leadership medical / scientific strategies of institutional portfolio of current,future products, based on customer needs,framed in corporate, local, values of Pfizer
policies.
Expert scientist portfolio in charge: Contribution,Leadership as leading expert in knowledge and management of medical, scientific strategies, through continuous,solid advice in development of projects portfolio in charge (Anti Infective), domain management information available regarding trademarks (medical studies, web pages, product portfolios, investigations, etc. - Scientific Medical Strategies: Design, lead, implement and Scientific doctor for hospital portfolio strategies: Infection prevention & Control strategies , Health partner coordination liaison , according to medical requirements, patients, health agencies, in order to provide services exceed expectations,maximize performance of brands. (Includes continuing medical education program,
forming expert committees, development and implementation of treatment guidelines, advice in construction of promotional material. - Comprehensive approach: active contribution from scientific point of view in development,implementation of medical strategies. 5) Strategic alliances: ensure solid relationships and partnerships with KOLs, scientific societies, health institutions and other key development portfolio by authorities.
- New products: Design, develop, implement scientific medical strategies for new brands, based on needs of physicians, patients,health agencies.
- Clinical Research, Health Economics: Participate in conjunction with clinical research area, areas of health economics in development of projects, plans, programs in order to contribute,create value in portfolio in charge.
- Regulatory: Medical support to regulatory strategy,products by developing,interaction with Colombian's regulatory agency (INVIMA); Medical lead for regulatory submissions,responses to Boards of Health.
- Provide medical leadership in development clinical study protocol,clinical study reports, RWE, Health Economics etc
Supervising MSLs activities. Supervising pharmacology resident activities in medical affairs department. - Co-creates as well as approves Locally/regionally promotional material. Zinforo /Zavicefta development plan for launching; including all knowledge generating activities (ie, value dossier,registration program, post approval commitments,lifecycle indications & phase 4 clinical studies.
- Accountable Locally for delivery of Global/Regional Medical Plan,ensuring single, aligned medical strategy, position on risk-benefit of asset, communication of that position internally & externally.
Leading Local Pfizer position on new data, competing assets, developing resistance, possible label changes, data generation. - Focus route through which evidence generation projects ( I4E) will be developed seeking alignment, synergies and support with global strategy teams, and studios local clinics as appropriate.
- Develop plan and execution of local real world evidence studies, including their design, analysis, specification, protocol development and publication linking methodologies of RWE and selection of data sources.
- Interact with different vendors (CROs, Medical writers, statisticians, etc.) to ensure compliance with objectives of RWE generation programs.
MEDICAL DIRECTOR(INFECTIOUS DISEASES DEPARTMENT)
SUBRED INTEGRADA DE SERVICIOS DE SALUD SUR OCCIDENTE E.S.E
BOGOTA, CUNDINAMARCA
11.2001 - 09.2020
- Used coordination and planning skills to achieve results according to schedule.
- Used Microsoft Word and other software tools to create documents and other communications.
- Managed team of 3 ID physicians adults, 2 ID physicians/pediatricians, 4 General physicians, 6 administrative personnel, 5 (Residents, Students) overseeing hiring, training, and professional growth of employees.
- Devoted special emphasis to punctuality and worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Delivered exceptional level of service to each customer by listening to concerns and answering questions.
- Worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Led ID team in delivery of Projects, productivity and other outcomes.
- Identified issues, analyzed information and provided solutions to problems.
- Completed all paperwork, recognizing any discrepancies and addressing them in timely fashion.
- Participated in continuous improvement by generating suggestions, engaging in problem-solving activities to support teamwork.
- Completed all task to ensure compliance with relevant regulations.
- Developed and implemented performance improvement strategies and plans to promote continuous improvement.
- Saved $ 200.000 USD per year by implementing cost-saving initiatives( ej Antimicrobial Stewardship Program ) that addressed long-standing problems.
- Created plans and communicated deadlines to ensure projects were completed on time.
- Carried out day-day-day duties accurately and efficiently.
- Associate instructor in infectious Diseases for Undergraduate and Postgraduate Medical students.
- Extensive Clinical/Research experience in Antimicrobial Stewardship Programs, Antimicrobial resistance,Antimicrobial's, Tropical Infectious diseases, Health care associated infections.
- Extensively Experience working in complex matrix team in private and public sectors.
- Optimized case and clinical management and recommended plans to improve safety and health programs.
- Devised plans to drive achievement of goals related to health, safety and employee relations.
- Contributed to strategic development of clinical programs and study reports.
- Verified effective, consistent communication between department heads, medical staff and governing boards by attending board meetings and synchronizing interdepartmental functions.
- Introduced and implemented new testing and interpretation procedures to maintain standards of care and meet quality assurance benchmarks.
- Oversaw clinic administration, including financial management, recruitment and human resources, training, program management and policy planning.
- Directed cost management, utilization management, quality assurance and medical protocol development initiatives.
- Identified new areas of scientific research and provided internal training.
- Administered financial management functions, including medical billing and collections, marketing and operational budgets.
- Led diverse team of medical and administrative professionals in day-to-day clinic activities such as patient care, new business development and patient relations.
- Attended variety of conferences to stay abreast of evolution of technology and implemented improvements in practice.
- Defined testing protocols, quality assurance initiatives and clinic policies and procedures.
- Worked with Pharmaceutical companies to conduct clinical trials in Infectious Diseases Area.
- Identified and maintained close professional relationships with influential physicians and researchers in medical community.
- Developed Timeframe objectives, goals and budgets in addition to devising suggestions to decrease spending.
- Collaborated with national and international organizations to leverage industry connections.
- Developed alliances with internal departments, including nursing, physical therapy and pharmacy units, resulting in improved communication and performance throughout region.
- Reviewed material used by medical team as part of Medical Review Board standards.
- Conducted literature and coding reviews to adhere to state and federal standards.
- Supervised Infectious Diseases Program and other resident education programs to facilitate quality patient care and improved treatment.
- Applied continuous process improvement strategies to enhance case management, programs and clinical management.
- Saved $200,000 USD by implementing cost-saving antimicrobial stewardship initiative as well as HIV/AIDS program.
MEDICAL MANAGER OUTCOME RESEARCH.
MERCK SHARP & DOHME (MSD) COLOMBIA. (SERVIMOS CONTRACTOR)
BOGOTA, CUNDINAMARCA
01.2013 - 07.2013
- Medial activities focus in patient centricity, putting patient first in all medical decisions related to any product.
- Proved successful working within tight deadlines, into fast-paced atmosphere.
- Developed, maintained courteous, effective working relationships.
- Prepared variety of different written communications, reports, documents to ensure smooth operations.
- Handled day-to-day running of Medical affairs Projects, ensuring high levels of productivity as well as progression.
- Devoted special emphasis to punctuality, worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Used Microsoft Word as well as other software tools to create documents and other communications.
- Collaborated with cross functional team achieve better outcomes for patients.
- Working Closely with Global Director ( Aurelio Otero) Anti invectives Portfolio across regions focus in Antimicrobial Stewardship and Business intelligence.
- Built and adapt research agenda in consultation with internal functions, key thought leaders and major stakeholder groups such as public health institutions and payers. Analysis of anticipated challenges and opportunities for optimization allows Lead projects to field realities and evolutions in disease, policy and regulatory contexts. Execute/monitor execution of research agenda ensuring - adequate and sound study design, - scientific excellence and strong compliance/integrity - efficient resource utilization .
- Make epidemiologic and real-world evidence available for decision making. Ensure research agenda integrates evidence dissemination strategy targeting impactful media/formats and key external stakeholders. Make use of expertise and maintain up-to-date knowledge of epidemiologic/observational methods, trends in disease and public health policies and regulations in order to deliver continuously relevant evidence analyses and expert advice to internal business and scientific functions in order to re-in force evidence-based decision making on development or commercial strategies, helping company to anticipate and adapt to changes in competitive and epidemiologic/public health contexts.
- Globally activities as team Leader. Study of Monitoring Antimicrobial Resistance Trends (SMART) Data generation Project: For Complicated Urinary Tract Infection cUTI, Complicated Intra abdominal Infections (c IAI) for: Colombia, Brazil, Mexico, CAAC, LATAM, Asia-Pacific, China, Servia.
- Burden of Herpes Zoster Diseases in Argentina, Costa Rica and Colombia.
- Managed team of 20 employees/contractors, overseeing hiring, training, and professional growth of employees.
- Participated in continuous improvement by generating suggestions, engaging in problem-solving activities to support teamwork.
- Conducted research, gathered information from multiple sources and presented results.
- Performed duties in accordance with all applicable standards, policies and regulatory guidelines to promote safe working environment.
- Completed all medical projects to ensure compliance with relevant Locally/Regionally regulations.
GLOBAL HEALTH OUTCOMES MERCK SHARP&DOHME ID FELLOW
UNIVERSITY OF SCIENCES IN PHILADELPHIA
LANDSDALE, PENNSILVANIA
01.2012 - 11.2012
- Delivered exceptional level of service to each Stake holders by listening to concerns answering questions.
- Worked to maintain outstanding attendance record, consistently arriving to work ready to start immediately.
- Prepared variety of different written communications, reports, documents to ensure smooth operations.
- Improved processes through consistent hard work dedication to Global women health projects.
- Participated in continuous improvement by generating suggestions, engaging in problem-solving activities to support teamwork.
- Offered friendly, efficient service to all stakeholders, handled challenging situations with ease.
- Carried out day-day-day duties accurately, efficiently.
- Created plans, communicated deadlines to ensure projects were completed on time.
- Maintained excellent attendance record, consistently arriving to work on time.
- Developed, implemented performance improvement strategies, plans to promote continuous improvement.
- Several's publications was delivered one of them was Editor Choice as Team lead/Leading author in Q1 Scientific Journal ( Healthcare expenses associated with multiple vs singleton pregnancies in United States. Elkin V Lemos, Dongmu Zhang, Bradley J Van Voorhis, X Henry Hu, American journal of obstetrics and gynecology 11/2013; 209(6). DOI: 10.1016/j.ajog.2013.10.005.
- Worked closely with Global Director Women Health (X Henry Hu) across regions (US non & US) in Women Health Portfolio as well as Infectious Diseases Portfolio.
CLINICAL EVIDENCE GENERATION.
WHO-UNAL
BOGOTA, COLOMBIA, CUNDINAMARCA
11.2009 - 12.2011
- Developed and implemented performance improvement strategies and plans to promote continuous improvement.
- Analyze Cost Of Effectiveness Of La Implementation Guide Tb - Multi drug resistance In Colombia Within Framework Of Colombia Tuberculosis-Free Plan And General System Of Social Security In Colombian Health.
- Resolved conflicts and negotiated mutually beneficial agreements between parties.
- Actively listened to customers, handled concerns quickly and escalated major issues to supervisor.
- Developed team communications and information for meetings.
Education. - Maintained energy and enthusiasm in fast-paced environment.
Oversaw daily operations to ensure high levels of productivity.
Led projects and analyzed data to identify opportunities for improvement. - Collaborated with Public Health Department to achieve outcomes.
Conducted [one] study on Costing of Tuberculosis and its impact in Colombian's system. - Led research team and successfully met key milestones
POSTDOCTORAL FELLOW INFECTIOUS DISEASES.
DEPARTMENT OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF TORONTO.
TORONTO, ONTARIO
07.2007 - 11.2010
- Wrote and published peer-reviewed articles concerning findings and highlighted possible applications for findings.
- Conducted in-depth research on biochemical, medical and behavioral data to apply to fellowship advance understanding.
- Attended research seminars, collegiate meetings to discover and discuss new technologies research.
- Upheld all university, regulatory requirements for documentation of findings.
- Worked independently in University basis for 3 years.
- Collaborated with colleagues to gather research, publish findings.
- Developed unique research into Health economics in Diabetic foot infections.
- Conducted research guided by faculty supervisor in accordance with institutional, federal guidelines.
- Reviewed analyzed historical,emerging literature to develop, practice new technologies.
- Enforced laboratory safety protocols enabled safe work environment.
- Authored professional scientific papers for publishing in peer-reviewed journals.
- Maintained records of research findings with analysis, evaluation of results.
- Worked to improve collective knowledge of Health economics applied to Infectious Diseases.
- Collaborated with Prince Margaret as well as Mount Sinai HCIs´ physicians to advance research, gain deeper understanding of Acinetobacter infections, as well as Diabetic foot infections.
- Completed analysis of data acquired from research, verified careful documentation of all information.
- Updated department leads on research-based findings, provided any shortfalls or advances of note.
- Taught 3 courses to students.
- Assisted teaching,instructing students alongside other professors.
- Participated in discussions, seminars, lectures at hot topics in infectious Diseases.
- Troubleshot, developed experimental tools to deal with ever-evolving technology.
INFECTIOUS DISEASES /SEXUALLY TRANSMITED INFECTION
ASOCIACIÓN PROBIENESTAR DE LA FAMILIA COLOMBIANA -PROFAMILIA-
BOGOTA D.C. COLOMBIA, CUNDINAMARCA
08.2006 - 07.2007
- Maintained energy and enthusiasm in fast-paced environment.
Developed and maintained courteous and effective working relationships. - Exceeded goals through effective task prioritization and great work ethic.
- Collaborated with Medical Director to achieve outcomes.
Created plans and communicated deadlines to ensure projects were completed on time. - Used critical thinking to break down problems, evaluate solutions and make decisions.
- Carried out day-day-day duties accurately and efficiently.
Maintained excellent attendance record, consistently arriving to work on time. - Supervised work of contracted employees to keep on task for timely completion.
- Offered friendly and efficient service to customers, handled challenging situations with ease.
- Handled 20 calls per day to address customer inquiries and concerns.
- Led projects and analyzed data to identify opportunities for improvement.
Education
Master of Arts - MASTER'S DEGREE iN GENERAL MANAGEMENT
UNIVERSITY E. MONTERREY
MEXICO 02.2019 - 05.2021
MBA - MASTER iN BUSSINESS ADMINISTRATION
EUROPEAN INSTITUTE oF POSTGRADUTE STUDIES(IEP)
MADRID, SPAIN 02.2019 - 05.2020
Master of Arts - MASTER EXECUTIVE iN PROJECT MANAGEMENT
EUROPEAN INTITUTE oF POSTGRADE STUDIES (IEP)
MADRID, SPAIN 02.2019 - 05.2020
No Degree - CERTIFICATION LEADERSHIP PROGRAM
MERCK INC/MSD
US 06.2013 - 12.2013
Master of Arts - HEALTH ECONOMICS AND PHARMACOECONOMICS
UNIVERSITAT POMPEU FABRA
BARCELONA, SPAIN 12.2009 - 12.2012
MERCK OUTCOMES RESEARCH ID FELLOW - OUTCOMES RESEARCH
UNIVERSITY oF SCIENCES
PHILADELPHIA, PENSILVANIA. USA. 01.2012 - 11.2012
Master of Science - MASTER 2010/2011 UPDATE iN VIH INFECTION
UNIVERSITY REY JUAN CARLOS
MADRID, SPAIN 03.2010 - 03.2011
POSTDOCTORAL FELLOW - HEALTH ECONOMICS iN INFECTIOUS DISEASES INFECTIONS
DEPARTMENT OF PHARMACEUTICAL SCIENCES
TORONTO, ONTARIO, CANADA. 07.2007 - 11.2010
Ph.D. - PUBLIC HEALTH
NATIONAL UNIVERSITY OF COLOMBIA
BOGOTA, COLOMBIA 02.2005 - 11.2010
No Degree - CLINICAL RESEARCH ASSOCIATE PROGRAM (ICH/GPC)
KRIGER RESEARCH CENTER
HUNTSVILLE, ONTARIO, CANADA 01.2008 - 12.2008
INFECTIOUS DISEASES SPECIALIST PHYSICIAN - INFECTIOUS DISEASES
NATION UNIVERSITY OF COLOMBIA
BOGOTA, COLOMBIA 02.1999 - 03.2003
M.D. - MEDICINE AND SURGERY
NATIONAL UNIVERSITY OF COLOMBIA
BOGOTA, COLOMBIA 06.1991 - 07.1997
Skills
Leadership communications
undefinedCertification
Licensed MD - Code 25699/98
Additional Information
PUBLICATIONS
1. Lemos Elkin V, Renteria Sixta, Cárdenas Paola, Ramos_Castañeda Jorge. In Vitro actividad de Ceftazidime-Avibactam Against Gram-Negative Strains in Colombia. Glob Antimicrob Resist 2022 Mar 4;S2213-7165(22)00053-4. doi: 10.1016/j.jgar.2022.02.018.
2. Karlowsky, J. A., Kazmierczak, K. M., de Figueiredo Valente, M. L. N., Luengas, E. L., Baudrit, M., Quintana, A., ... & Sahm, D. F. (2021). In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019. The Brazilian Journal of Infectious Diseases, 25(6), 101647.
3. Ramos-Castaneda, J. A., Ruano-Ravina, A., Osorio-Manrique, J., Barreto-Mora, J., Segura-Cardona, A. M., & Lemos-Luengas, E. V. (2021). Effect of Antibiotic Prophylaxis on Infectious Complications in Patients with Asymptomatic Bacteriuria Undergoing Urologic Surgery. Revista Urología Colombiana/Colombian Urology Journal, 30(03), e157-e164.
4. Varón-Vega, F. A., Lemos, E., Castaño, G. N., & Reyes, J. M. (2021). Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia. Expert review of Pharmacoeconomics & outcomes Research, 1-6.
5. Kazmierczak, K., Valente, M. L., Lemos, E., Baudrit, M., Quintana, A., Irani, P., ... & Sahm, D. F. (2020, October). 1580. In Vitro Activity of Ceftazidime-Avibactam Against Enterobacterales and Pseudomonas aeruginosa Collected in Latin America as part of the ATLAS Global Surveillance Program, 2017-2019. In Open Forum Infectious Diseases (Vol. 7, No. Supplement_1, pp. S788-S788). US: Oxford University Press
6. Cortés, J. A., Ruiz, J. F., Melgarejo-Moreno, L. N., & Lemos, E. V. Candidemia en Colombia ,Biomédica. 2020 40(1).
7. Varón-Vega, F. A., Castaño, N., Lemos, E., & Reyes, J. M. (2020). Cost-effectiveness analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to carbapenem-resistant Enterobacteriaceae in Colombia
8. Ramos-Castaneda, J. A., Ruano-Ravina, A., Salinas, D. F., Osorio-Manrique, J., Segura-Cardona, A. M., & Lemos-Luengas, E. V. (2019). Factors associated with multidrug-resistant bacteria in a cohort of patients with asymptomatic bacteriuria who underwent urological surgery. American journal of infection control, 47(12), 1479-1483.
9. Ramos-Castaneda, J. A., Ruano-Ravina, A., Muñoz-Price, L. S., Toro-Bermúdez, R., Ruiz-Londoño, D., Segura-Cardona, A. M., & Lemos-Luengas, E. V. (2019). Risk of infection in patients undergoing urologic surgery based on the presence of asymptomatic bacteriuria: A prospective study. American journal of infection control, 47(12), 1474-1478.
10. Guerrero, C. C., De La Hoz, F., Eslava-Schmalbach, J., Camerano, R., & Luengas, E. L. (2019). PIN25 CALIDAD DE REVISIONES SISTEMATICAS CON EVALUACIONES DE COSTO-EFECTIVIDAD DE LA VACUNA CONTRA ROTAVIRUS DE PAISES LATINOAMERICANOS. Value in Health Regional Issues, 19, S44.
11. Paillier-Gonzalez, J. E., Saldaña-Campos, J. C., Salinas, D. F., & Lemos-Luengas, E. V. (2018). Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis. J Infection, 76(5), 438-448.
12. Correa, C., Castro, E., Salamanca, D., Bustacara, L., & Lemos, E. (2017). Escherichia Coli productora de Nueva Delhi metalo-β-lactamasa en Colombia: reporte de caso. Infectio, 21(2), 132-134.
13. Ramos, J. A., Lemos, E. V., & Ruano-Ravina, A. (2017). Duration of surgical antibiotic prophylaxis in patients with asymptomatic bacteriuria. The Lancet Infectious Diseases, 17(4), 370.
14. Ramos, J. A., Lemos, E. V., & Ruano-Ravina, A. (2017). Duration of surgical antibiotic prophylaxis in patients with asymptomatic bacteriuria. The Lancet Infectious Diseases, 17(4), 370.
15. Rodríguez-Martínez, C. E., Sossa-Briceño, M. P., & Lemos, E. V. (2015). Cost-effectiveness analysis of mometasone furoate versus beclomethasone dipropionate for the treatment of pediatric allergic rhinitis in Colombia. Advances in therapy, 32(3), 254-269.
16. Yang, H. K., Dasbach, E. J., Guarin, D., Hernandez, G., & Lemos, E. (2015). Assessing the public health impact and cost effectiveness of pneumococcal vaccines for adults 65 years of age in Colombia. Value in Health, 18(7), A871.
17. Rodriguez-Martinez, C. E., Sossa-Briceño, M. P., & Lemos, E. V. (2015). Evaluación Económica De Los Principales Esteroides Intranasales Utilizados Para El Tratamiento De Pacientes Pediátricos Con Rinitis Alérgica En Colombia. Value in Health, 18(7), A840.
18. Lemos, E. V., de la Hoz, F. P., Alvis, N., Einarson, T. R., Quevedo, E., Castañeda, C., ... & Kawai, K. (2014). Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clinical Microbiology and Infection, 20(2), 174-180.
19. Rosenthal, V. D., Maki, D. G., Mehta, Y., Leblebicioglu, H., Memish, Z. A., Al-Mousa, H. H., ... & Zhu, L. International Nosocomial Infection Control Consortiu (INICC) (2014). report, data summary of 43 countries for 2007-2012. Device-associated module. American journal of infection control, 42(9), 942-956.
20. Lemos, E. V., de La Hoz, F. P., Einarson, T. R., McGhan, W. F., Quevedo, E., Castañeda, C., & Kawai, K. (2014). Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clinical Microbiology and Infection, 20(5), 416-423.
21. Pavía, J., Lemos, E. V., Restrepo, M., & Lozano, F. (2014). Análisis del impacto presupuestal de mometasona/formoterol en enfermedad pulmonar obstructiva crónica en Colombia. Revista Colombiana de Neumología, 26(2).
22. Lemos E, Sweet, D. E., Zhuo, D. Y., Macalalad, A. R., & Signorovitch, J. (2014). Cost-Effectiveness Of Ertapenem Versus Ceftriaxone in Treating Urinary Tract Infections in Colombia. Value in Health, 17, A1-A295.
23. Xie, Y., Lemos, E., Restrepo, M., Ruiz, J., & Lozano, F. (2014). Cost-Effectiveness Of Ertapenem Versus Piperacillin/Tazobactam in In Treating Community Acquired Intra-Abdominal Infections in Colombia. Value in Health, 17(3), A273.
24. Luengas, E. V. L. (2014). Selección de la opción costo-efectiva para Colombia en la detección de toxoplasmosis congénita en el recién nacido. Infectio, 17(2).
25. Lemos, E. V., de la Hoz, F. P., Alvis, N., Quevedo, E., Einarson, T. R., Castañeda, C., & Kawai, K. (2013). Costos en pacientes con infección por Acinetobacter baumannii en Colombia. Infectio, 17(4), 185-192.
26. Lemos-Luengas, E., Quevedo-Franco, E., & Castro-Solarte, E. (2013). Correlación inversa entre Carga Viral y recuento de Linfocitos t cd4 entre pacientes VIH/Sida atendidos en un hospital distrital de Bogotá. Medicina, 35(1), 29-40.
27. Villa, L. M., Cortés, J. A., Leal, A. L., Meneses, A., & Meléndez, M. P and GREBO. (2013). Pseudomonas aeruginosa resistente a antimicrobianos en hospitales colombianos. Revista chilena de infectología, 30(6), 605-610.
28. Guerrero, C. C., Eslava, J., Ruiz, A., Diaz, J., Prieto, V., & Lemos, E. V. (2013). Costo-Efectividad Del Uso De Pruebas Treponémicas Rápidas Para La Detección Y Tratamiento Temprano De Sífilis Gestacional En Colombia. Value in Health, 16(7), A668.
29. Lemos, E., & Hu, H. (2013). Comparison of Gonadotropin Utilization between GnRH Agonist and Antagonist Protocols–A Meta-analysis. Fertility and Sterility, 99(3), S18.
30. Lemos, E. V., Zhang, D., Van Voorhis, B. J., & Hu, X. H. (2013). Healthcare expenses associated with multiple vs singleton pregnancies in the United States. (EDITORIAL CHOICE) American journal of obstetrics and gynecology, 209(6), 586-e1.
31. Vujacich, C., De Wouters, L., Margari, A., Gordóvil, M., Kawai, K., Lemos, E., ... & Sampalis, J. S. (2013). Assessment of burden of illness due to herpes zoster in Argentina: a prospective observational study. Value in Health, 16(7), A668.
32. Rosenthal, V. D., Bijie, H., Maki, D. G., Mehta, Y., Apisarnthanarak, A., Medeiros, E. A., ... & Jayatilleke, K. International Nosocomial Infection Control Consortium (INICC) (2012). report, data summary of 36 countries, for 2004-2009. American journal of infection control, 40(5), 396-407.
33. Molina, F. J., Cortes, J. A., Soto, R., Lemos, E. V., Gutiérrez-Ardila, M. V., & Núñez, S. M. (2012). PIN31 Cost-Effectiveness Analysis of Antifungal Treatments Available in Colombia for the Treatment of Invasive Candidiasis. Value in Health, 15(4), A242.
34. Lemos, E. V., Cortes, J., Gutiérrez-Ardila, M. V., Nuñez, S. M., & Prieto, H. A. (2012). PIN36 Cost-Effectiveness Analysis of Voriconazole Versus Amphotericin B Deoxycholate in the Treatment of Invasive Pulmonary Aspergillosis in Colombia. Value in Health, 15(4), A243.
35. Lemos, E. V., De la Hoz Restrepo, F., Alvis, N., Quevedo, E., Cañon, O., & León, Y. (2011). Mortalidad por Acinetobacter baumannii en unidades de cuidados intensivos en Colombia. Revista Panamericana de Salud Pública, 30, 287-294.
36. Lemos, E., Izquierdo, C., Caceres, H. A., & Cortes, J. (2010). PIN27 Cost_Effectivness Analysis of the theraphy for the invasive aspergilosis in Colombia. Value in Health, 3(13), A191.
37. Luengas, E. L., Castañeda, B. C., Quevedo, E., Castillo, C., & Lemos, L. R. (2010). The economic impact of introducing HIV/AIDS guideline into Colombian National Drug Formulary. Cost-effectiveness analysis. International Journal of Infectious Diseases, 14, e242-e243.
38. Molina, F. J., Cortes, J. A., Caceres, H. A., Soto, R., Luengas, E. L., & Imbanaco, C. M. (2010). Cost-effectiveness analysis of the therapy for the invasive Candidiasis in Colombia. International Journal of Infectious Diseases, 14, e123.
39. Chow, I., Lemos, E. V., & Einarson, T. R. (2008). Management and prevention of diabetic foot ulcers and infections. Pharmacoeconomics, 26(12), 1019-1035.
40. Chow, I., Lemos, E. V., & Einarson, T. R (2008) Pharmacoeconomic Analysis of Guidelines for Treating Mild Diabetic Foot Infections: A Decision-Tree Model for Canada. Can J Hosp Pharm 2008;61(6):412–421.
41. Lemos, E. V., Castañeda, C., Chow, I., Marr, P., Machado, M., & Einarson, T. R. (2008). PIN12 Pharmacoeconomic Analysis Based on guidelines for treating mild analysis based on Guidelines for treating mild Diabetic Foot Infectins: A Decision Model for Colombia. Value in Health, 3(11), A95-A96.
42. Tillotson, G. (2007). (Lemos E) Highlights from the 45th IDSA annual meeting. Treatment Outcomes of Patients with Bloodstream Infections caused by ESBL Producing Enterobacteriaceae the Lancet Infectious Diseases, 7(12), 769.
43. Garzón, J., Lemos, E., & Rivas, R. (2004). Prevalencia de betalactamasas de espectro extendido en Escherichia coli, Klebsiella pneumoniae y Klebsiella oxytoca del Hospital Occidente de Kennedy. Nivel III, Bogotá. Revista ciencias de la salud, 2(2), 124-138.
44. Knudson, A., Lemos, E., Ariza, Y., Salazar, M., Chaves, M. D. P., PATRICIA, R., ... & Sánchez, R. (2003). Frequency of E. vermicularis infection in rural schoolchildren in Quipile, Colombia, 2001. Revista de Salud Pública, 5(1), 87-99.
1. Luengas, E. L., Sarmiento, M. C., & Moneada, L. I. (2001). Defensinas: una nueva perspectiva en antibioticoterapia. Revista de la Facultad de Medicina, 49(4), 207-209.
1. Luengas, E. L., Sarmiento, M. C., & Moneada, L. I. (2001). Defensinas: una nueva perspectiva en antibioticoterapia. Revista de la Facultad de Medicina, 49(4), 207-209.
45. Luengas, E. L., Sarmiento, M. C., & Moneada, L. I. (2001). Defensinas: una nueva perspectiva en antibioticoterapia. Revista de la Facultad de Medicina, 49(4), 207-209.
PUBLICATIONS (2010-2020) (26 more relevant RWE) Citations: 309; Reads 1778 (https://www.researchgate
Highly impacted Publications focused in Infectious Diseases, Antimicrobial resistance, Health economics related to Infectious Diseases.
Awards/honors/recognitions
2020 LATAM Medical Excellence Award( Nomination in Courage bold move)
2020 Global marketing, Hospital Business Unit, Pfizer Medrol Matters Crowdsourcing Challenge-Special Awards. Convenience to Customers.
2019 Pfizer price of excellence Huellas Second semester Outstanding contribution
2018 Award Colombian team project I4E. Pfizer Global. R & D Quality
2017 Pfizer price of excellence Huellas Second Semester “Leadership and commitment”
2017 Pfizer price of excellence Huellas Year 2017 “Leader and Outcomes”
2015. MSD Colombia 2015 MSD Excellence Awards Months: July Special Achievement Award
2014 (GHH) Global acure care hospital Merck, Co, Inc. White House Station NJ USA Award of Excellence
2014. MSD Colombia 2014 MSD Excellence Awards Months: June, October) Results Orientation Award (June) Strategic Thinking Award (October) 2013. MSD Colombia 2013 MSD Excellence Awards Month: September Agility Award
2013 The Royal Society of Medicine. 1 Wimpole Street London W1G0AE England Young Epidemiologist Prize
2009 Colegio Agustiniano de San Nicolás Bogotá, Colombia Recognition and Merit, while within the College and Throughout the career
2008 International Society of infectious diseases 1330 Beacon Street, Suite 228 Brookline, MA 02446 USA Scientific Exchange Fellowship Award 2008 Government of Canada CBIE, Attention Julita Palka 220 Laurier Avenue West, Suite 1550 Ottawa, ON K1P 5Z9 Graduate Students' Exchange Program (GSEP) Award
2005/2007 2005-2010 Universidad Nacional de Colombia Doctorate En Salud Publica. Bogota, Colombia. Extension of 50% payment of tuition and appreciation For being in the highest scores on the Universidad Nacional De Colombia.
2005 ICETEX-Ministerio de la Protection Social. Loan Forgiveness-Grant total for completion within the Time frames and obtaining an overall average of 4.7/5.0 in the medical specialty in infectious diseases at the National University of Colombia. 1979/1990 Colegio Agustiniano de San Nicolás Bogotá Colombia. Full Scholarship for high academic achievement
VOLUNTERING
Global COVID-19 Medical Service. Pfizer will provide the opportunity for certain colleagues to provide medical service support to countries and communities to deliver emergency medical care in response to the COVID-19 pandemic. Approval for medical service is limited to providing support for diagnosing, treating and providing public health support for COVID-19, be it voluntarily or mandatory medical service required by local, regional or national authorities.
(20-04-2020) -(20-07-2020) WHO: The World Health Organization (WHO): is the organism of the United Nations Organization (UN) specialized in managing policies of prevention, promotion and intervention at world level in health, defined in its Constitution as a state of complete physical well-being, mental and social, and not only as the absence of affections or diseases/ Description of role/required duties at organization WHO: Since the coronavirus spread throughout the world (pandemic), the World Health Organization among other lines of action has established a Response Fund, in which approximately 175 thousand recognized people and institutions have collaborated In this framework, the governing body in the management of health prevention, promotion and intervention policies is promoting a study called Solidarity (solidarity); This is a project promoted by WHO worldwide. It is a large clinical trial worldwide to verify which is the most effective treatment against coronavirus. Dr Lemos has been invited to participate in it. Activities in Bogota.
(20-04-2020) -(20-07-2020) Bogotá District Health Secretariat-Bogota: Governing body in health in Bogotá D.C. responsible for guaranteeing the right to health through a comprehensive and integrated care model and governance, to contribute to improving the quality of life of the population of the Capital District. Capital. Description of role/required duties at organization: will be public Health Support based in data bases analysis of information regarding COVID19 in Bogotá, effective collaboration, regarding participating as a co-author with contributions from your academic training and medical-scientific expertise(systematic review of the literature and health economic, epidemiological analysis, public health and medical view ), systematic review of the literature for a preparation of an Article called "The challenge of controlling the Corona-virus Pandemic in Bogotá: D -2020", focusing in Epidemic description in Bogotá, Current diagnosis and Management of Covid-19, and its Biological Plausibility.
view ), systematic review of the literature for a preparation of an Article called "The challenge of controlling the Corona-virus Pandemic in Bogotá: D -2020", focusing in Epidemic description in Bogotá, Current diagnosis and Management of Covid-19, and its Biological Plausibility.
PROFESIONAL MEMBERSHIPS
Asociación Colombiana de Infectología (ACIN)
International Society for Pharmacoeconomic and Outcomes Research (ISPOR)
Society of Infectious Diseases Pharmacist (SIDP)
American Society for Microbiology (ASM)
The Society for Healthcare Epidemiology of America (SHEA)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
JOURNAL REVIEWER
Infectio
Annals of Pharmacotherapy
Value in Health Medical Sciences
Monitor
New Microbes and New infection Journal
HOBBIES
CHESS
TENNIS TABLE
BASKETBALL
READING
TRAVELLING.
STATEMENT OF INTERESTS
Medical Affairs Direction, Medical Quality function, Infectious Diseases, Rapid Diagnosis in Infectious Diseases, Microbiology testings, Professional external relations, Real World Data Generation, HEOR, Burden of Diseases, Budget impact analysis, Public health, Epidemiology, Antimicrobial Stewardship (AMS), Antimicrobial resistance Surveillance
Timeline
HOSPITAL MEDICAL LEAD COLOMBIA-VENEZUELA
PFIZER S.A.S
02.2021 - Current
Master of Arts - MASTER'S DEGREE iN GENERAL MANAGEMENT
UNIVERSITY E. MONTERREY
02.2019 - 05.2021
MBA - MASTER iN BUSSINESS ADMINISTRATION
EUROPEAN INSTITUTE oF POSTGRADUTE STUDIES(IEP)
02.2019 - 05.2020
Master of Arts - MASTER EXECUTIVE iN PROJECT MANAGEMENT
EUROPEAN INTITUTE oF POSTGRADE STUDIES (IEP)
02.2019 - 05.2020
MEDICAL MANAGER ANTI-INFECTIVES
PFIZER SAS
03.2016 - 02.2022
No Degree - CERTIFICATION LEADERSHIP PROGRAM
MERCK INC/MSD
06.2013 - 12.2013
MEDICAL MANAGER OUTCOME RESEARCH.
MERCK SHARP & DOHME (MSD) COLOMBIA. (SERVIMOS CONTRACTOR)
01.2013 - 07.2013
MERCK OUTCOMES RESEARCH ID FELLOW - OUTCOMES RESEARCH
UNIVERSITY oF SCIENCES
01.2012 - 11.2012
GLOBAL HEALTH OUTCOMES MERCK SHARP&DOHME ID FELLOW
UNIVERSITY OF SCIENCES IN PHILADELPHIA
01.2012 - 11.2012
Master of Science - MASTER 2010/2011 UPDATE iN VIH INFECTION
UNIVERSITY REY JUAN CARLOS
03.2010 - 03.2011
Master of Arts - HEALTH ECONOMICS AND PHARMACOECONOMICS
UNIVERSITAT POMPEU FABRA
12.2009 - 12.2012
CLINICAL EVIDENCE GENERATION.
WHO-UNAL
11.2009 - 12.2011
No Degree - CLINICAL RESEARCH ASSOCIATE PROGRAM (ICH/GPC)
KRIGER RESEARCH CENTER
01.2008 - 12.2008
POSTDOCTORAL FELLOW - HEALTH ECONOMICS iN INFECTIOUS DISEASES INFECTIONS
DEPARTMENT OF PHARMACEUTICAL SCIENCES
07.2007 - 11.2010
POSTDOCTORAL FELLOW INFECTIOUS DISEASES.
DEPARTMENT OF PHARMACEUTICAL SCIENCES, UNIVERSITY OF TORONTO.
07.2007 - 11.2010
INFECTIOUS DISEASES /SEXUALLY TRANSMITED INFECTION
ASOCIACIÓN PROBIENESTAR DE LA FAMILIA COLOMBIANA -PROFAMILIA-
08.2006 - 07.2007
Ph.D. - PUBLIC HEALTH
NATIONAL UNIVERSITY OF COLOMBIA
02.2005 - 11.2010
MEDICAL DIRECTOR(INFECTIOUS DISEASES DEPARTMENT)
SUBRED INTEGRADA DE SERVICIOS DE SALUD SUR OCCIDENTE E.S.E
11.2001 - 09.2020
INFECTIOUS DISEASES SPECIALIST PHYSICIAN - INFECTIOUS DISEASES
NATION UNIVERSITY OF COLOMBIA
02.1999 - 03.2003
M.D. - MEDICINE AND SURGERY
NATIONAL UNIVERSITY OF COLOMBIA
06.1991 - 07.1997
Similar Profiles
Zein KasboZein Kasbo
Scientist at Pfizer Vaccines, Molecular Biology Group, PfizerScientist at Pfizer Vaccines, Molecular Biology Group, Pfizer
César Augusto Rojas SierraCésar Augusto Rojas Sierra
Infra Team Part Leader at LG CNS Colombia S.A.S.Infra Team Part Leader at LG CNS Colombia S.A.S.
Athos DimatoreAthos Dimatore
Hotel Manager at Gente De Mar S.A.SHotel Manager at Gente De Mar S.A.S